Insider Buying: SCYNEXIS, Inc. (NASDAQ:SCYX) CEO Purchases $27,400.00 in Stock

SCYNEXIS, Inc. (NASDAQ:SCYX) CEO Gonzalez David Angulo bought 20,000 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The shares were acquired at an average price of $1.37 per share, for a total transaction of $27,400.00. Following the completion of the transaction, the chief executive officer now owns 507,871 shares in the company, valued at $695,783.27. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

SCYNEXIS Trading Down 1.3 %

Shares of SCYX opened at $1.57 on Thursday. The stock’s 50-day moving average price is $1.78 and its two-hundred day moving average price is $1.82. SCYNEXIS, Inc. has a 12 month low of $1.26 and a 12 month high of $3.66. The company has a market capitalization of $59.31 million, a PE ratio of 0.77 and a beta of 1.50.

SCYNEXIS (NASDAQ:SCYX) last announced its earnings results on Thursday, August 8th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.11). SCYNEXIS had a negative net margin of 366.09% and a negative return on equity of 57.41%. The company had revenue of $0.74 million during the quarter. Equities research analysts predict that SCYNEXIS, Inc. will post -0.68 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, StockNews.com downgraded shares of SCYNEXIS from a “hold” rating to a “sell” rating in a research note on Monday, August 12th.

Institutional Investors Weigh In On SCYNEXIS

Several large investors have recently modified their holdings of the company. Simplicity Wealth LLC acquired a new position in SCYNEXIS in the first quarter valued at $29,000. Empowered Funds LLC increased its holdings in SCYNEXIS by 8.1% in the first quarter. Empowered Funds LLC now owns 88,414 shares of the company’s stock worth $130,000 after purchasing an additional 6,650 shares in the last quarter. Acadian Asset Management LLC lifted its stake in SCYNEXIS by 5.4% in the first quarter. Acadian Asset Management LLC now owns 421,083 shares of the company’s stock valued at $618,000 after buying an additional 21,700 shares during the period. AMH Equity Ltd boosted its holdings in shares of SCYNEXIS by 19.9% during the 1st quarter. AMH Equity Ltd now owns 660,000 shares of the company’s stock worth $970,000 after buying an additional 109,600 shares in the last quarter. Finally, D.A. Davidson & CO. grew its position in shares of SCYNEXIS by 8.3% during the 4th quarter. D.A. Davidson & CO. now owns 526,490 shares of the company’s stock worth $1,174,000 after buying an additional 40,164 shares during the period. 54.37% of the stock is currently owned by institutional investors and hedge funds.

SCYNEXIS Company Profile

SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.